Merck Manual

Please confirm that you are a health care professional

honeypot link

Lincosamides, Oxazolidinones, and Streptogramins

By

Brian J. Werth

, PharmD, University of Washington School of Pharmacy

Last full review/revision May 2020| Content last modified May 2020
Click here for Patient Education

Lincosamides (clindamycin), oxazolidinones (linezolid, tedizolid), and streptogramins (dalfopristin [streptogramin A] and quinupristin [streptogramin B]) are structurally different but are grouped together because they have a similar mode of antibacterial action and similar antibacterial spectra. Macrolides and chloramphenicol may be included with this group for similar reasons. All inhibit protein synthesis by binding to the 50S ribosomal subunit.

Certain methyl-transferase enzymes can mediate resistance to multiple members of the above classes. The erythromycin resistance methylase (erm) gene commonly mediates resistance to macrolides, clindamycin, and quinupristin but not the oxazolidinones or dalfopristin. The chloramphenicol-florfenicol resistance (cfr) gene mediates resistance to chloramphenicol, dalfopristin, clindamycin, and oxazolidinones, but tedizolid may retain susceptibility in some strains. Certain multidrug efflux pumps can also produce cross-resistance between some of these classes as well.

Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Test your knowledge

Common Cold
The common cold is an acute, self-limited viral infection that causes upper respiratory symptoms that last for approximately 10 days. Susceptibility to colds is most affected by which of the following? 
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID

Also of Interest

Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
TOP